{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:15:33Z","timestamp":1767827733595,"version":"3.49.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The simultaneous occurrence of multiple myeloma (MM) and chronic myeloid leukemia (CML) is an extremely rare event that has been reported in only eight cases in the literature. We report here on only the third case of the development of MM in a patient with CML on treatment with imatinib mesylate, and to our knowledge, this is the first case in a patient who received imatinib as first-line treatment.<\/jats:p>","DOI":"10.1634\/theoncologist.2009-0165","type":"journal-article","created":{"date-parts":[[2009,12,3]],"date-time":"2009-12-03T02:10:46Z","timestamp":1259806246000},"page":"1198-1200","source":"Crossref","is-referenced-by-count":16,"title":["Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months"],"prefix":"10.1093","volume":"14","author":[{"given":"Michalis","family":"Michael","sequence":"first","affiliation":[{"name":"Haematology Department of Nicosia General Hospital, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Antoniades","sequence":"additional","affiliation":[{"name":"Haematology Department of Nicosia General Hospital, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Lemesiou","sequence":"additional","affiliation":[{"name":"Haematology Department of Nicosia General Hospital, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicandros","family":"Papaminas","sequence":"additional","affiliation":[{"name":"Haematology Department of Nicosia General Hospital, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freiderikh","family":"Melanthiou","sequence":"additional","affiliation":[{"name":"Haematology Department of Nicosia General Hospital, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2021122207042694700_R1","first-page":"170","article-title":"Multiple myeloma preceding the development of chronic myelogenous leukemia","volume":"69","author":"Nitta","year":"1999","journal-title":"Int J Hematol"},{"key":"2021122207042694700_R2","first-page":"1047","article-title":"Multiple myeloma superimposed on chronic myelocytic leukemia","volume":"110","author":"Derghazarian","year":"1974","journal-title":"Can Med Assoc J"},{"key":"2021122207042694700_R3","first-page":"995","article-title":"Light chain disease (hypogammaglobulinemia and Bence-Jones proteinurea) and sideroblastic anemia-preleukemic chronic granulocytic leukemia","volume":"106","author":"MacSween","year":"1972","journal-title":"Can Med Assoc J"},{"key":"2021122207042694700_R4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3349\/ymj.1993.34.3.293","article-title":"Multiple myeloma and chronic myelogenous leukemia\u2014a case report with literature review","volume":"34","author":"Klenn","year":"1993","journal-title":"Yonsei Med J"},{"key":"2021122207042694700_R5","first-page":"132","article-title":"Coexistance of multiple myeloma and chronic myelogenous leukemia","volume":"70","author":"Tanaka","year":"1999","journal-title":"Int J Hematol"},{"key":"2021122207042694700_R6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.leu.2402971","article-title":"Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: Evaluation by FISH analysis and in vitro expansion of bone marrow cells","volume":"17","author":"Schwarzmeier","year":"2003","journal-title":"Leukemia"},{"key":"2021122207042694700_R7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.35.3.364","article-title":"Simultaneous presentation of chronic granulocytic leukaemia and multiple myeloma","volume":"35","author":"Boots","year":"1982","journal-title":"J Clin Pathol"},{"key":"2021122207042694700_R8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1634\/theoncologist.10-6-457","article-title":"Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate","volume":"10","author":"Garipidou","year":"2005","journal-title":"The Oncologist"},{"key":"2021122207042694700_R9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00277-008-0597-2","article-title":"Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"88","author":"Galanopoulos","year":"2009","journal-title":"Ann Hematol"},{"key":"2021122207042694700_R10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2021122207042694700_R11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajh.2830330203","article-title":"VAD-based regimens as primary treatment for multiple myeloma","volume":"33","author":"Alexanian","year":"1990","journal-title":"Am J Hematol"},{"key":"2021122207042694700_R12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.1365-2141.2003.04706.x","article-title":"Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents","volume":"123","author":"Pandiella","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122207042694700_R13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","article-title":"Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen\u2019s disease patients","volume":"14","author":"Teo","year":"2000","journal-title":"J Biochem Mol Toxicol"},{"key":"2021122207042694700_R14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","article-title":"Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: A translational perspective","volume":"16","author":"La Ros\u00e9e","year":"2002","journal-title":"Leukemia"},{"key":"2021122207042694700_R15","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/sj.leu.2403949","article-title":"Zolendronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells","volume":"19","author":"Chuah","year":"2005","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2021122207042694700_R16","first-page":"101a","article-title":"In vitro effects of PS-341 alone and in combination with STI571 in Bcr-Abl positive cell lines both sensitive and resistant to STI571","volume":"98","author":"Gatto","year":"2001","journal-title":"Blood"},{"key":"2021122207042694700_R17","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/12\/1198\/41841477\/oncolo_14_12_1198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/12\/1198\/41841477\/oncolo_14_12_1198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:05:12Z","timestamp":1640156712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/12\/1198\/6398886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,1]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2009,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0165","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,12,1]]},"published":{"date-parts":[[2009,12,1]]}}}